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Abstract 
 
Chronic kidney disease (CKD) has become a worldwide public health 
priority and is estimated to affect approximately 12% of the global 
population.  CKD is associated with an increased cardiovascular 
morbidity, premature mortality, and a substantial economic burden.   
 
Increased generation of reactive oxygen species has been observed 
throughout CKD progression, suggesting that mitochondrial 
dysfunction may be important in the pathogenesis of kidney disease.  
The mitochondrial genome is a circular double stranded DNA 
molecule composed of 16,569 base pairs harbouring 37 genes, which 
encode 13 key proteins of the electron transport chain along with two 
rRNAs and 22 tRNAs.  At least 2,309 nuclear genes are also necessary 
for efficient mitochondrial function. Mitochondrial dysfunction leads 
to a reduction in ATP production, cellular damage and loss of renal 
function.  Damage or mutations in mtDNA will lead to defects in 
mitochondrial oxidative phosphorylation (OXPHOS), which can result 
in a range of clinical symptoms involving several different organs 
broadly termed as ‘mitochondrial diseases’.  Defects in nuclear 
encoded genes may also lead to OXPHOS defects, abnormal protein 
translation and loss of mtDNA copy number.   
 
This review provides an update on molecular features influencing 
mitochondrial homeostasis and function, highlighting how these are 
compromised during CKD. 
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Introduction 
Chronic kidney disease (CKD) is a worldwide public health priority and is estimated to currently 
affect between 11–13% of the global population.1  CKD is associated with increased cardiovascular 
morbidity, premature mortality and a substantial healthcare cost.2,3 Gradual decline in kidney 
function in individuals with CKD involves dysfunction of several biological pathways, including 
altered cellular metabolism, nitrogen balance and protein metabolism changes, insulin resistance 
and increased production of mediators of inflammation and oxidative stress.4–7 Increased generation 
of reactive oxygen species (ROS) has been observed at throughout progressive stages of CKD and it 
has been suggested that this may be the result of mitochondrial dysfunction.8   
 
Mitochondria are responsible for generation of adenosine triphosphate (ATP) to provide energy to 
eukaryotic cells via a series of oxidative phosphorylation (OXPHOS) reactions known as the electron 
transport chain (ETC). Mitochondria also regulate cellular metabolism via heme and steroid 
synthesis, generating ROS, establishing the membrane potential and controlling calcium and 
apoptotic signalling.9,10 It is thought that these cellular powerhouses (Fig. 1) originated through an 
endosymbiotic relationship with an α-proteobacterium.11 Although many mitochondrial genes are 
now located on nuclear chromosomes these organelles contain their own circular genome 
reminiscent of their bacterial ancestors.12,13 By transferring a substantial amount of genetic material 
to the nuclear genome the size of the mitochondrial genome is greatly reduced, which may impart a 
replicative advantage and reduce the likelihood of incurring disadvantageous mutations, thus 
reinforcing the idea of a synergistic relationship between these two genomes.14  
 
Among human body organs, the kidneys are second to the heart in terms of energy demands, 
mitochondrial content and oxygen consumption.15,16 This is necessary to produce the energy 
required for removal of waste from blood, reabsorption of nutrients, regulation of electrolyte and 
fluid balance, maintenance of acid–base homeostasis, and regulation of blood pressure.17 
Mitochondria also provide the energy required by Na+–K+-ATPase to create ion gradients across the 
cellular membrane and to facilitate active transport in the proximal tubule, the loop of Henle, the 
distal tubule and the collecting duct to allow ion reabsorption and excretion.18 Energy demands, and 
in turn mitochondrial content are much higher in the proximal tubules compared with the 
glomerulus as glomerular filtration is a passive process whereas the proximal tubules require a large 
variety of active transport mechanisms in order to reabsorb 80% of the filtrate that passes through 
the glomerulus.19 Because of these high energy requirements, mitochondrial dysfunction in the 
kidneys may severely impact renal health and has previously been implicated in CKD development. 
 
CKD is typically defined as kidney structure or function abnormalities persisting for more than three 
months and impacting on the health of the individual.20 As the body ages the kidneys undergo age-
related structural changes along with a reduction in functional capacity.  In adults over 35 years, 
kidneys gradually lose functional nephrons and decrease in size so that by 80 to 85 years old many 
individuals will have lost up to 30% of total kidney mass.21 Although many older people with reduced 
kidney mass will continue to have normal kidney function there is a reduction in the “margin of 
safety” which in turn will impact on the kidneys’ ability to respond to stress placed upon remaining 
nephrons such as infection or reduced blood flow.21 Many elderly people will exhibit a low 
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glomerular filtration rate (GFR) but without any specific kidney disease. It is therefore important to 
understand the underlying genetic causes of kidney disease and decreasing renal function in order to 
design more effective therapies and reduce the associated healthcare burden.22,23 Persistent 
reduced kidney function, with or without proteinuria measured by albumin creatinine ratio (ACR), is 
indicative of CKD and is associated with damage to kidney tubules and glomeruli. Although the 
underlying cause of reduced renal function in CKD may vary between individuals, there are several 
pathways involved with CKD development including accumulation of extracellular matrix (ECM) 
proteins in the glomerulus, interstitial fibrosis, tubular atrophy and inflammation. Over the last 
decade, several genetic risk factors have been identified and robustly associated with CKD.24–27 
 
Mitochondrial Genetics  
Genes required for normal mitochondrial function are found on both mitochondrial DNA (mtDNA) 
and nuclear DNA (nDNA). The mitochondrial genome is a circular double stranded DNA molecule 
composed of 16,569 base pairs harbouring 37 genes encoding 13 key proteins of the ETC along with 
two rRNAs and 22 tRNAs (Fig. 1).12 In contrast to nDNA, mtDNA lacks introns and non-coding 
intergenic regions, apart from a small regulatory region between the mitochondrial genes for 
phenylalanine and proline tRNAs known as the non-coding region (NCR). This 1.1 kb stretch of DNA 
frequently contains a third single strand of DNA 650 nucleotides long (7S DNA) which forms a 
displacement-loop, or D-loop28, postulated to be an mtDNA replication intermediate29–31, facilitating 
more open conformation of the mtDNA molecule, allowing proteins involved in replication or 
transcription to bind and regulate these activities.32,33 Although the exact mechanism of replication 
in mtDNA is not yet fully understood, a number of nuclear encoded enzymes are essential to this 
process.34–39 
 
In humans, mtDNA passes to offspring through maternal gametes. As each mitochondrion contains 
multiple copies of maternally inherited mtDNA, and each cell contains many mitochondria, it is 
possible for mutations to occur during replication which will affect some mtDNA molecules but not 
others; this phenomenon is known as heteroplasmy and contributes to disease development.40 
During an individual’s lifetime the actions of ROS and the resulting mtDNA mutations are thought to 
be directly involved in various disease mechanisms and the process of aging.41 
 
There are at least 2,526 autosomal genes involved with mitochondrial function. Many nuclear 
encoded mitochondrial genes (NEMGs) code for proteins which are synthesised on ribosomes in the 
cytosol, migrate to the mitochondria, and are transported across the mitochondrial membrane 
based on the presence of a specific N-terminal presequence.42 Other NEMGs do not code directly for 
mitochondrial components but regulate the expression of a range of genes which are essential for 
normal mitochondrial biogenesis and function. 
 
 
 
Mitochondria and Chronic Kidney Disease 
 
 
Science Publishing Group Copyright 2019 www.spg.ltd 
 
4 
Mitochondria and nuclear gene interactions 
Mitochondrial dysfunction may be due to inherited germline or acquired somatic mutations. For 
example, acquired damage to tubular mitochondria alters mitochondrial dynamics, mitophagy and 
biogenesis in acute kidney injury which is risk factor subsequently for CKD.43  
 
RecQ-like helicase 4 (RECQL4) is a dynamic protein important for protein-protein interactions in 
nDNA replication but also localises to the mitochondrion where it interacts with POLγ in order to 
maintain mtDNA integrity.44 RECQL4 mutations result in increased mtDNA copy number and 
mitochondrial dysfunction.45 This protein may also act to regulate p53 tumour mitochondrial 
transport while RECQL4 dysfunction may decrease p53 activity.46 Data from immunofluorescence 
microscopy suggest that DNA2 molecules are mainly found in mitochondria where they have been 
shown to interact with Polγ and Twinkle.47,48 These interactions may be important in repairing 
oxidative lesions in mtDNA, mtDNA maintenance and protection against mtDNA related diseases.48,49 
Petite integration frequency 1 (PIF1) is a member of the superfamily 1 helicase family that acts in 
both nuclei and mitochondria.50–56 A DExH-box helicase known as suppressor of Var1 3-Like Protein 1 
(SUV3) is thought to be indirectly involved in mtDNA stability and copy number regulation.57  SUV3 is 
important in regulating mitochondrial RNA levels and may also interact with nDNA replication and 
repair factors in the nucleus.58–61   
 
These interactions between mtDNA and nDNA highlight the symbiotic relationship between 
mitochondrial organelle and the nucleus. Due to this relationship, dysfunction of genes in mtDNA or 
nDNA can have devastating consequences and mitochondrial dysfunction is strongly implicated in 
kidney disease. 
 
Mitochondria and CKD 
More than 250 genes involved with mitochondrial energy metabolism have been associated with 
human disease62 and this mitochondrial damage may occur due to direct mtDNA insult or NEMG 
defects.63 Damage or mutations in mtDNA may lead to primary defects in mitochondrial OXPHOS 
due to dysfunction of the ETC components, which can result in a range of clinical symptoms involving 
several different organs broadly termed as, ‘mitochondrial diseases’. Mutations in mtDNA often 
have a greater functional impact than variants in nuclear-encoded mitochondrial genes; several 
mtDNA genes are known to affect kidney function (Table 1).  
 
For example, mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) 
syndrome are mitochondrial cytopathies resulting from defects in MT-ND1 and MT-ND5 which 
encode for complex I proteins, as well as MT-TH, MT-TL1, and MT-TV which code for mitochondrial 
tRNAs.64 NEMG insults may also lead to OXPHOS defects, abnormal protein translation, and lower 
mtDNA copy number.65 Traditional mitochondrial diseases often include renal complications, due to 
an mitochondrial abundance as well as kidney high energy demands e.g. defects in CoQ10 synthesis 
and the mtDNA 3243 A>G mutation are known to cause renal complications including focal 
segmental glomerulosclerosis.43,66–72 Tubular defects are the most common renal manifestation of 
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mitochondrial disorders from mutations in mtDNA or NEMGs. Mitochondrial isoleucine tRNA gene 
(tRNAIle) mutations have been associated with familial hypercholesterolemia and 
hypomagnesaemia.73 Fanconi syndrome which is secondary to kidney tubular dysfunction has been 
linked with mutations in the gene EHHADH.74 Five nuclear genes (COQ5, COX6A1, GATC, TOP1MT 
and PARCRG) have been linked to kidney disease in people with type 1 diabetes, across multiple 
cohorts.75 
 
Thirty-eight NEMGs are reported to be involved with CKD development (Table 2; Supplementary 
Table 1), with many having important roles in maintaining mitochondrial function and renal health. 
NEMGs dysregulation because of acquired or inherited mutations can affect several pathways which 
may initiate a vicious cycle aggravating renal damage and leading to CKD (Fig. 2). Many NEMGs are 
essential for mitochondrial biogenesis and normal mitochondrial function, particularly PPARGC1A 
which regulates TFAM, COX6C, COX7C, UQCRH, MCAD, SIRT3, and NRF1.76 PPARGC1A and its 
downstream targets are reported to be downregulated in peripheral blood mononuclear cells of CKD 
patients. PPARGC1A induction by ROS may act as a protective adaption to reduce further ROS 
generation.77  
 
Other genes involved with mitochondrial biogenesis are upregulated in CKD in response to increased 
ROS production, these include NFE2L2 (regulated by PPARGC1A), SOD2, Complex 1 components 
(NDUFS5, NDUFA6, NDUFA1 and NDUFB1), UQCRH, UQCRB, ATP5I, ATP5J, and ATP5O.77–79 
Upregulation of these genes may be an attempt to compensate for increased ROS generation 
resulting from OXPHOS dysfunction. Genes coding for complex IV 6C and 7C subunits (COX6C and 
COX7C) were also seen to be upregulated in CKD, however, complex IV activity was reduced due to 
chronic oxidative stress and oxidant injury resulting from OXPHOS system inhibition.11 Damage to 
nDNA and mtDNA can arise from various sources (Supplementary Table 2) and DNA damage may 
compromise or bypass repair mechanism increasing the frequency of mutations.  
 
Several studies have investigated SNPs associated with chronic kidney disease (Table 3). Damage to 
both NEMGs and mtDNA genes may have an impact on mitochondrial function due to ineffectual 
clearance of ROS which may further exacerbate mitochondrial damage and lead to increased ROS 
production due to AIFM180 downregulation and NOX4 upregulation.81,82 This vicious cycle of ROS 
production results in oxidative stress within the mitochondria leading to ATG5 and BECN1 
downregulation,83 which may lead to abnormal or impaired autophagy which in turn leads to further 
ROS generation, dysregulated mitochondrial fission and reduced mitochondrial function.83–85 BNIP3 
is an important mediator of mitophagy and upregulation of this gene has been associated with 
sarcopenia in CKD along with decreased mtDNA copy number and reduced mitochondrial function.86 
The intrinsic pathway of apoptosis has also been implicated in CKD. Downregulation of the anti-
apoptotic protein BCL-xL coded for by BCL2L1 combined with upregulation of pro-apoptotic BAX and 
BAK1 leads to increased apoptosis and depolarisation of the outer mitochondrial membrane in 
proximal tubular cells. BAX upregulation and BCL2L1 downregulation activates the intrinsic apoptotic 
pathway, permeabilising the inner mitochondrial membrane leading to cytochrome C release.87–89  
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Uncontrolled apoptosis may eventually lead to inflammation and fibrosis commonly observed in 
CKD. Experimental CKD models have shown increased expression of several genes involved with 
inflammation and fibrosis. TGFβ expression increases in response to apoptosis in primary tubular 
cells exposed to albumin stimulating ECM formation and the extrinsic apoptotic pathway.90,91 PPARγ 
upregulation is common in several forms of renal disease and affects renal parenchymal cells 
stimulating various pathways important in CKD development including fibrotic, inflammatory, 
immune, proliferative, reactive oxygen and mitochondrial injury pathways.92 NLRP3 upregulation 
and downstream targets CASP1, IL-18, and IL-1β are upregulated in CKD in response to 
mitochondrial ROS generation. Activation of the NLRP3 inflammasome leads to increased ECM 
deposition, apoptosis and fibrosis of renal cells. NLRP3 knockout or ROS inhibition reduce 
mitochondrial dysfunction, reduce apoptosis, decrease ECM deposition and protect against renal 
fibrosis.93–96 
 
Mitochondrial dysfunction resulting from inherited or acquired genetic defects may lead to 
development of various forms of kidney disease such as acute kidney injury, diabetic nephropathy, 
glomerular diseases, tubular diseases and CKD.43,97,98 In summary, mitochondrial dysfunction and 
OXPHOS defects may increase ROS generation and reduce ATP production which leads to increased 
oxidative stress which may lead to uncontrolled autophagy, mitophagy and further ROS production. 
Mitochondrial dysfunction, ROS generation and the resulting dysregulation of autophagic 
mechanisms may also lead to an upregulation of the intrinsic pathway of apoptosis which in turn 
leads to inflammation and fibrosis in the renal tubules, glomerulus and podocytes. This damage may 
then generate further autophagy leading to apoptosis, fibrosis and inflammation with further 
podocyte function reduction eventually leading to irreversible podocyte injury and progression to 
CKD. 
 
NEMGs involved with podocyte function may play a key role in the progression of CKD. Cathepsin D, 
coded for by CTSD, is a lysosomal proteinase involved with lysosomal degradation, autophagic 
degradation and contributes to maintaining podocyte homeostasis. CTSD may be downregulated or 
inactivated in CKD and loss of this protein leads to impaired autophagy, resulting in the 
accumulation of toxic subunit c–positive lipofuscins and slit diaphragm proteins followed by 
apoptotic cell death.99 ITCH expression is increased in mouse models of kidney disease.100 This gene 
is regulated by the Src kinase Fyn and modulates various signalling pathways including TGFβ and EGF 
through ubiquitin and non-ubiquitin mediated mechanisms.101–104 Interactions with Fyn, TGFβ and 
related signalling molecules may suggest a role of ITCH in regulating glomerular sclerosis and 
podocyte function.100 Downregulation of NRP2 was observed in animal models of kidney disease and 
NRP2 knockout mice displayed progressive glomerular damage when exposed to a podocyte 
toxin.100,105 
 
Epigenetic features affecting mitochondrial in CKD  
Epigenetic modifications affect gene expression without directly altering the DNA sequence. These 
changes can be inherited between generations or may result from environmental exposures 
acquired during a lifetime.106,107 Known epigenetic mechanisms include DNA methylation108,109,110, 
histone modifications111, regulation by non-coding RNA, and chromatin remodelling112–114. Epigenetic 
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modifications resulting from an adverse in utero environment have been implicated in increased risk 
of several diseases such as cardiovascular disease, hypertension, type 2 diabetes mellitus, obesity 
and renal disease.115–120 A systematic review by White and colleagues121 reported that low birth 
weight individuals (<2.5 Kg at birth) have an increased CKD risk of in adulthood. Epigenetic changes 
are also acquired throughout life often in response to adverse conditions such as the high-glucose 
environment experienced in diabetes mellitus.122 The role of epigenetic modifications in kidney 
disease have previously been discussed in detail elsewhere123–126 and methylation of nuclear DNA 
and histone modifications are known to influence CKD development, particularly in patients with 
diabetes.127,128 Genes involved with renal development and renal fibrosis have also been found to be 
differentially methylated in persons with CKD.129–135 Amongst these differentially methylated genes 
the top canonical pathways included oxidative phosphorylation and mitochondrial dysfunction.135 
DNA hypermethylation was also observed on the PGC-1α promotor region in diabetic patients and 
was inversely correlated with mitochondrial content.136,137 Recent studies using cell lines devoid of 
mitochondria demonstrated that depletion of mitochondrial DNA can lead to abnormal CpG 
methylation patterns and restoration of mtDNA in these cells partially reverse these changes.138 This 
highlights the ability of mitochondria and nDNA to interact through both genetic and epigenetic 
mechanisms. Due to this complex interaction, mitochondrial dysfunction will affect both the nuclear 
and the epi-genome.  Resulting bioenergetics failure is implicated in a number of energy deficiency 
diseases particularly in tissues which rely on high energy flux including brain, heart, muscle, renal, 
and endocrine systems.139,140 Within the context of renal disease, mitochondrial proteins ability to 
cause epigenetic modifications has been demonstrated through the ability of mitofusion 2 to abate 
histone acetylation in the promoter region of collagen IV through a reduction in ROS generation, in 
turn reducing collagen IV expression in streptozotocin-induced diabetic rats.141–144  
 
Historically, there was much debate surrounding the mtDNA ability to undergo epigenetic 
changes.145–151 However, in 2011 advances in methodology and sensitivity demonstrated the 
presence of methylated bases in human mtDNA.152 Shock and colleagues showed that a DNMT1 
transcript variant was present inside mitochondria where it is capable of modifying transcription of 
the mitochondrial genome.153 Also around this time, Chestnut and colleagues observed DNMT3a in 
mitochondria of mouse and human tissue, providing evidence that DNA methylation may act on 
mtDNA by similar mechanisms as in nDNA.154 In mtDNA  methylated cytosines are mainly located in 
non-CpG moieties within the mitochondrial D-Loop, particularly in the promotor region of the heavy 
strand and in conserved sequence blocks of the  which may indicate a role in regulating mtDNA 
replication or transcription.155 In addition to cytosine methylation mtDNA also contains 
hydroxylmethylated cytosine at a higher density than in autosomes in both the D-Loop region and 
along the entire mitochondrial genome.155,156 MtDNA is protein coated and contained within 
nucleoids.157–159 Histone family members, particularly H2A and H2B, have also been observed in 
mitochondria although rather than directly binding DNA these were found to localise to the 
mitochondrial membrane.160 In 2008 Bogenhagen and colleagues161 found 57 proteins associated 
with human mtDNA. Amongst these, there are several proteins essential for mitochondrial 
biogenesis as well as for mtDNA transcription and replication including Mitochondrial transcription 
factor A, mitochondrial transcription factor B, DNA polymerase gamma, prohibitin, Twinkle helicase 
and mitochondrial single-stranded DNA binding protein.159,162–165 Whole genome and transcriptome 
sequencing has also revealed the presence of numerous ncRNAs including siRNAs, miRNAs and 
lncRNAs which are involved with regulating essential signalling pathways in mitochondria by altering 
expression of nuclear-encoded mitochondrial proteins.166–172 In addition to ncRNAs encoded by 
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nDNA, Rackham and colleagues173 identified three lncRNAs transcribed by the mitochondrial genome 
from regions complementary to ND5, ND6 and Cytb genes. These mitochondrial lncRNAs are 
regulated by the mitochondrial RNase P complex and their abundance varies significantly across 
different tissue types with a high abundance observed in cardiac tissue.173,174 There are also 
thousands of non-coding small RNAs transcribed by mtDNA the majority of which are derived from 
sense transcripts of mitochondrial genes, but these have also been mapped to the mitochondrial D-
loop region.175,176 
 
In addition to external environmental stress, altered metabolic states such as hyperglycaemia in 
diabetes or uraemia in CKD can also lead to epigenetic changes known as hyperglycaemic or uremic 
“memory”, respectively.177–179 Epigenetic features are potential therapeutic targets as they may be 
reversible and tissue specific, therefore they may be attractive potential foci for drugs targeting 
specific epigenetic changes. For example, epigenetic changes associated with diabetic nephropathy 
can be reversed by losartan treatment in diabetes mouse models.123,180–182 
 
Conclusions 
Persistent mitochondrial dysfunction is known to be involved in the initiation and progression of 
renal diseases, such as acute kidney injury and diabetic nephropathy, resulting from disruption to 
mitochondrial homeostasis and normal kidney function.19 Oxidative stress is a common CKD feature 
and increased production of reactive oxygen species due to mitochondrial dysfunction has been 
observed in diabetes, inflammation and aging.183 Increased ROS production due to mitochondrial 
dysfunction may also contribute to CVD and other co-morbidities associated with CKD.86,183,184 
Further investigation into mitochondria roles in maintaining renal health and their contribution to 
various forms of CKD may unveil new disease mechanisms as well as novel treatments. Significant 
genetic damage or mutations in NEMGs may also disrupt mitochondrial homeostasis. The cellular 
machinery and related genes involved in mitophagy, mitochondrial fission, fusion and biogenesis are 
essential in maintaining mitochondrial homeostasis and dysfunction of these processes may lead to 
irreversible kidney damage. There is evidence to suggest that mitochondrial dysfunction precedes 
CKD development, occurring in the early stages of acute kidney injury and diabetic nephropathy, 
failure to restore mitochondrial function may then initiate the vicious cycles outlined earlier 
resulting in CKD.185 The use of multi-omic approaches to investigate CKD are providing valuable 
insights; the integrated use of these techniques will allow a better understanding of mitochondria 
influencing in renal disease. 
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Table 1 Defects in Mitochondrial DNA previously associated with kidney complications  
Variation Type Variation Region Phenotype References 
Point mutation mtDNA 3243 A>G mutation MT-TL1 MELAS, MERRF syndrome and MIDD 
67,68,186–188
 
Point mutation c.550A>G MRPS7 Substitution of valine for a highly conserved methionine 
(p.Met184Val) observed in case report of  Congenital 
sensorineural deafness, progressive hepatic and renal 
failure and lactic academia 
⁠189 
Point mutation m.12425delA MTND5 Renal failure and myopathy resulting from Complex I 
deficiency 
190
 
Point mutation m.G586A 
 
mt-tRNA
Phe 
 
 
 
 
TIN 
191
 
m.A608G 
 
mt-tRNA
Phe 
 
⁠192 
 
m.3243 
 
mt-tRNA
Leu 
 
193,194
 
 
m.A5656G Noncoding 
195
 
Point mutation m.G3242A mt-tRNALeu Renal failure, RTA type 4 
196
 
Point mutation m.3243 
 
 
 
mt-tRNA
Leu 
 
 
 
FSGS 
194,196–202
 
m.A4269G mt-tRNA
Ile 203
 
m.A5728G mt-tRNA
Asn 204
 
m.A5843G mt-tRNA
Tyr
 
205
 
Point mutation m.12425delA ND5 Glomerulocystic disease, renal failure 
190
 
Deletion 6,000 bp ∼6,000–12,000 Proximal tubulopathy 206 
Deletion 7,500 bp ∼6,100–13,600 FSGS, RTA 207 
Deletion 8,800 bp ∼6,800–15,600 Distal tubulopathy 208 
Deletion 7,315 bp 
 
7,325–14,639 
 
Proximal tubulopathy, TIN 
 
209
 
 
2,800 bp 
 
∼10,000–12,800 
 
Proximal tubulopathy, TIN 
 
210
 
 
5,700 bp 
 
∼8,400–14,100 
 
Proximal tubulopathy 
 
211
 
4,977 bp 
 
8,469–13,447 
 
Proximal tubulopathy 
 
212,213
 
2,608 bp 10,598–13,206 TIN 
214
 
SNPs 
 
73A\G 
146T\C 150C\T 194C\T 
195T\C 310T\C 
mtDNA D-loop 1122 bps 
from nucleotide 16,024–
16,569 and 1–576 
 
These D-loop SNPs are associated with risk of CKD and 
kidney survival time in those with CKD. SNPs in this region 
may affect mtDNA replication and lead to electron transport 
chain alteration, therefore increasing ROS generation and 
may contribute to nuclear genome damage. 
215
 
MELAS - Mitochondrial Encephalopathy, Lactic acidosis, and Stroke-like episodes; MERRF syndrome - 
Myoclonic epilepsy with ragged-red fibers; MIDD - Maternally-inherited diabetes and deafness; TIN – 
Tubulointerstitial nephritis; RTA – Renal Tubular Acidosis; FSGS - Focal segmental glomerulosclerosis; SNP – 
Single Nucleotide Polymorphism; CKD – Chronic Kidney Disease; ROS – Reactive Oxygen Species  
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 Table 2 Nuclear encoded mitochondrial genes involved with development of chronic 
kidney disease (more details in supplementary table 1)   
Biological Process Genes and expression in CKD  Pathological Effect of gene expression  
Mitochondrial 
Biogenesis and 
Function 
Downregulated: PPARGC1A; 
NRF1; TFAM; UQCRH; COX6C and 
COX7C in PBMC of CKD patients 
undergoing PD; MCAD; AIFM1 
 
Upregulated: COX6C and COX7C 
in PBMC of CKD (stage IV – V) 
patients in conservative 
treatment and HD; NFE2L2; SOD2; 
NDUFS5; NDUFA6; NDUFA1; 
NDUFB1; UQCRB; ATP5I; ATP5J; 
ATP5O; APOL1; NOX4 
PPARGC1A downregulation may be protective adaption to limit ROS production.  
Will also reduce expression of downstream targets of NRF-1 and PGC1α and 
reduce mitochondrial biogenesis and OXPHOS activity.  
Downregulation of TFAM may lead to decreased mtDNA copy number.   
Expression of NFE2L2, SOD2 and UQCRH may also be associated with increased 
ROS generation.  
Increased expression of Complex I proteins. Complex V proteins and UQCRB may 
be an attempt to restore OXPHOS mechanisms.  
Reduced Complex IV activity may be associated with OXPHOS defects  
Increased expression of renal risk variants of APOL1 and NOX4 may increase 
mitochondrial damage by ROS. 
Apoptosis (Intrinsic 
Pathway) 
Downregulated: BCL2L1; AIFM1 
 
Upregulated: BAX; BAK1; HIF1 
Reduced expression of BCL-xL allows BAX expression and mitochondrial 
accumulation to increase which increases apoptosis and depolarises outer 
mitochondrial membrane in proximal tubular cells.  Increased BAX expression 
also permeabilises the inner mitochondrial membrane leading to cytochrome C 
release 
AIFM1 inactivation results in OXPHOS defects 
Activation of HIF1 promotes renal cell growth, stimulates angiogenesis, and 
reduces inflammation 
Autophagy and 
Mitophagy 
Downregulated: ATG5; CTSD; 
BECN1 
 
Upregulated: BNIP3 
Downregulation of ATG5; CTSD; BECN1 may lead to impaired autophagy and 
increased ROS production, mitochondrial deformation and decreased 
mitochondrial function  
Increased expression of BNIP3 may indicate increased mitophagy and reduced 
mitochondrial function 
Inflammation and 
fibrosis 
Upregulated: NLRP3; CASP1; 
PPARG; TGFβ 
NLRP3 inflammasome is activated by mitochondrial ROS which, increases ECM 
deposition, apoptosis, fibrosis of renal cells and CASP1 expression.  
Upregulation of PPARG effects renal parenchymal cells a well as fibrotic, 
inflammatory, immune, proliferative, reactive oxygen and mitochondrial injury 
pathways 
Apoptosis in Primary tubular cells exposed to albumin has been shown to 
increase TGFβ expression which stimulates ECM formation and the extrinsic 
apoptotic pathway 
Podocyte Function   Downregulated: NRP2; KLF6; CTSD 
 
Upregulated: ITCH 
Downregulation of NRP2 in CKD may contribute to podocyte damage 
Podocyte specific KLF6 loss increased susceptibility to FSGS in mice models 
Downregulation of CTSD in podocytes may lead to impaired autophagy and 
eventually apoptotic cell death 
ITCH expression may be important in regulating glomerular sclerosis and 
podocyte function 
PBMC – Peripheral blood mononuclear cell; CKD – Chronic kidney disease; PD – peritoneal dialysis; HD - haemodialysis; ROS 
– Reactive oxygen species; OXPHOS – Oxidative phosphorylation; mtDNA – mitochondrial DNA; ECM – Extracellular matrix  
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Table 3 Examples of SNPs in nuclear encoded mitochondrial genes previously associated with chronic 
kidney disease   
Phenotype Gene Top Ranked 
SNPs 
Statistics Protein function in 
Mitochondria 
Population Notes References 
eGFR 
 
 
 
 
 
 
 
 
NAT8  rs13538 P = 4.5 x10-14 May be involved in 
regulation of apoptosis  
Meta 
Analyses of 
GWAS from 
individuals of 
European 
ancestry 
Common variants in 
NAT8 may influence 
acetylation 
pathways, 
disturbances of 
which are known to 
be involved with 
drug and toxin 
induced kidney 
injury. 
216
 
SLC22A2 rs2279463 P = 5.5 x10-12 Evidences for 
mitochondrial localisation  
Mediates cation 
reabsorption in 
kidney  
216
 
WDR72 rs139926232   
 
 
rs491567 
P = 7.20x10
-11
   
Beta = 0.0083 
 
P = 2.7E-13 
 
May be involved in 
localization of the calcium 
transporter SLC24A4 to 
the ameloblast cell 
membrane. Expressed in 
cytosol and mitochondria    
Also involved with 
positive regulation of 
lipid metabolic 
process and abnormal 
glucose homeostasis  
216,217
 
 
 
 
Diabetic 
Nephropathy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AFF3 rs7583877 P = 1.2×10−8  
OR = 1.29  
(95% CI: 1.18–
1.40) 
Encodes a transcriptional 
activator, with DNA-
binding activity 
3 discovery 
cohorts from 
GENIE 
consortium: 
UK-ROI, 
FinnDiane and 
GoKinD US 
Influences renal 
tubule fibrosis 
24
 
MYO16- 
IRS2 
rs9521445  
 
 
 
rs1411766 
P = 4.4×10−3  
OR = 1.25  
(95% CI: 1.07–
1.46) 
 
P = 0.03  
OR = 1.19  
(95% CI: 1.01 
–1.40) 
IRS2 has been seen to 
localise to mitochondria 
and is associated with DM  
90% 
Caucasian 
from Joslin 
Clinic 
including 
patients from 
all social 
strata   
These SNPs are found 
in an intergenic 
region telomeric to 
MYO16 and 
centromeric to IRS2. 
Associated with CKD 
in T2DM subjects.   
Not significant after 
Bonferroni correction  
218
 
COQ5 rs1167726 
 
rs614226 
P = 2.00×10
−5
 
 
P = 2.00×10
−5
 
Encodes 
methyltransferase  which 
is located in 
mitochondrial matrix  
All people 
included in 
the analysis 
were of white 
European 
origin and 
were 
diagnosed 
Associated with both 
DKD and ESRD in the 
discovery and in silico 
replication analyses 
subjects with T1DM  
75
 
COX6A1 rs12310837 P = 3.00×10
−5
 Subunit 6A1 of 
cytochrome c oxidase 
which is the terminal 
75
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enzyme of the 
mitochondrial respiratory 
chain 
with T1DM 
before the 
age of 31 
years GATC rs2235222 
 
rs7137953 
P = 4.00×10
−5
 
 
P = 4.00×10
−5
 
Glutamyl-TRNA 
Amidotransferase Subunit 
C is required by 
mitochondria for 
formation of correctly 
charged  Gln-tRNA(Gln) 
75
 
TOP1MT rs724037 P = 2.00×10
−4
 
 
Encodes a mitochondrial 
DNA topoisomerase that 
plays a role in the 
modification of DNA 
topology 
75
 
PACRG rs2147653 P = 0.004 
 
Coregulated with  PARK2 
which plays a key role in 
regulation of 
mitochondria function via 
mitophagy 
75
 
CYBA  -675 T → A 
 
 
 
 
 
C242T 
P = 0.0354  
OR = 0.38 
 
 
 
 
P = 0.015 HR 
= 2.1 
CYBA encodes p22phox 
subunit which are 
essential for the function 
of NOX/NADPH oxidases 
Age and 
gender 
matched 
Caucasian 
subjects with 
and without 
type 1 
diabetes  
CYBA -675 T → A 
 modulate the risk for 
renal disease in the 
studied population of 
type 1 diabetes 
patients  
 
C242T correlates 
with 
microalbuminuria 
onset in the French 
T1DM cohort   
219,220
 
GCLC  rs17883901 P = 0.0068 
OR = 2.40 CI 
95% 1.27-4.56 
Modulates the risk for 
renal disease in the 
studied population of 
T1DM patients 
Associated with 
cellular redox 
imbalances  
219
 
SIRT1 rs4746720 T>C 
 
 
rs2236319 A>G 
 
 
rs10823108 
G>A 
 
 
P = 0.041 OR 
= 0.88  
(CI 95%: 0.77–
0.99) 
 
P = 0.044 OR 
= 1.12   
(CI 95%: 1.00–
1.24) 
 
P = 0.038 OR 
= 1.12   
(CI 95%: 1.01–
Involved with regulation 
of aging, longevity, and 
pathogenesis of age-
related metabolic 
diseases, such as T2DM 
 
Japanese 
cohort of 
T2Dm 
4 SNPs were 
nominally associated 
with diabetic 
nephropathy 
however the 
haplotype consisting 
of 11 SNPs within 
SIRT1 had a stronger 
association than 
individual SNPs   
221
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rs3818292 A>G  
 
 
Haplotype 
TATAGATAGTA 
1.24) 
 
P = 0.042 OR 
= 1.12   
(CI 95%: 1.01–
1.24) 
 
P = 0.0091 
OR= 1.34  
(CI 95%: 1.07–
1.66) 
SOD2 rs2758329 C>T 
 
 
 
 
rs8031 A>T 
 
 
 
rs4880 C>T 
 
 
P = 0.005 OR= 
2.08   
(CI 95%: 1.26–
3.53) 
 
P = 0.009 OR= 
1.99 (CI 95%: 
1.20–3.36) 
 
P = 0.005 OR= 
2.16 (CI 95%: 
1.28–3.72) 
Catalyses the dismutation 
of superoxide into oxygen 
and hydrogen peroxide to 
maintain proper 
mitochondrial biogenesis 
and function  
Caucasian 
subjects with 
type 1 
diabetes 
from the 
SURGENE 
prospective 
study 
These SNPS were 
associated with 
incipient 
nephropathy and 
decline of eGFR in 
prospective study.  
Associated with 
established/advance
d nephropathy in 
follow-up 
222
 
 
 
 
Ala9Val 
 
P = 0.001  
OR= 1.780 
Detoxify and reduce 
production of 
superoxide and other 
free radicals 
Subjects were 
South Indian 
primarily of 
Dravidian 
origin and 
North Indian 
of Indo-
European 
origin with 
T2DM for 
more than 10 
years  
Wild-type alleles may 
confer greater 
survival ability to 
comorbid 
complications and 
may be 
nephroprotective 
223
 
 
UCP1  
 
−112 T>G 
 
 
P = 0.012  
OR = 2.076 
 
223
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Ala64Thr 
 
P = 0.015
  
OR = 2.099 
 
NOS3 Glu298Asp P = 0.002  
OR = 2.103 
223
 
 
GSTP1 Ile105Val, A>G P = 0.003  
OR = 1.888 
223
 
 
Membranous 
Nephropathy 
PLA2R1 rs35771982 
 
 
 
rs3749117 
 
 
 
rs4664308 
P = 1.90 x10
-30
  
OR = 2.36  
(CI 95%: 2.03 
to 2.74) 
 
P = 2.23x10
-29
  
OR = 2.32  
(CI 95%: 2.00 
to 2.69) 
 
P = 4.17x10
-30
  
OR = 2.35 
(CI 95%: 2.02 
to 2.73) 
Induces cell death in a 
mitochondrial ROS-
dependent manner which 
may play an important 
role in tumour 
suppression  
The 
population 
under 
investigation 
consisted of 
Chinese 
subjects with 
and without 
idiopathic 
membranous 
nephropathy 
Closely associated 
with circulating anti-
PLA2R antibodies in 
serum as well as the 
expression of PLA2R 
in glomeruli.  
224
 
HLA-
DQA1 
rs2187668 P = 1.11x10
-14
  
OR= 2.42  
(CI 95%: 1.93 
to 3.05) 
Evidence for localisation 
in mitochondria  
Belongs to the HLA 
class II alpha chain 
paralogues and plays 
a central role in the 
immune system by 
presenting peptides 
derived from 
extracellular proteins. 
224
 
IgA 
Nephropathy 
ITGAM  rs7190997  
 
 
rs11574637 
 
P = 2.26 × 
10
−19
   OR= 
1.22 
 
P = 8.10 × 
10
−13
  
OR= 1.32 
 
Mitochondria-associated 
ER Membrane protein 
Subjects were 
of Chinese 
Han ethnicity 
with and 
without IgA 
nephropathy  
Alpha M beta 2 
integrin is important 
in the adherence of 
neutrophils and 
monocytes to 
stimulated 
endothelium, and 
also in the 
phagocytosis of 
complement coated 
particles.  
Downregulated in 
diabetes 
225
 
NODAT ATF6 rs2340721 P = 0.05  Activator of mTOR which 
acts as a key sensor for 
Subjects were 
of Caucasian 
This SNP has been 
associated with an 
226–229
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OR= 0.21  
(CI 95%: 0.04–
1.0) 
mitochondrial and B cell 
nutrient status through 
interactions with PPARG 
and PPARGC1A 
origin tested 
for diabetes 7, 
90 and 365 
days after 
kidney 
transplant 
increased BMI in a 
renal transplant 
cohort, pre-diabetes 
in a Chinese cohort, 
and has been found 
in tight linkage 
disequilibrium (in 
Caucasians) with 
rs2070150 which is 
associated with T2DM 
in Pima Indians  
PPARG rs1801282 P = 0.02  
OR = 8.5 
(CI 95%: 1.4–
52.7) 
Regulated by mTOR and 
promote cell growth, 
proliferation, metabolism 
and survival.  
Previously associated 
with T2DM 
226,230
 
PPARGC
1A  
rs8192678  P = 0.03  
OR= 0.26 
(CI 95%: 0.08–
0.91) 
226,231
 
FSGS 
 
APOL1 G1 allele 
(rs73885319 
and 
rs60910145) 
 
 
G2 allele 
(rs71785313) 
P = 1.07 × 
10
−23 
P = 1.1 × 10
−39 
 
 
 
P = 4.38 × 
10
−7 
 
 
  
Encodes a secreted high-
density lipoprotein which 
binds to apolipoprotein 
A-I. Apolipoprotein A-I is 
a relatively abundant 
plasma protein and is the 
major apoprotein of HDL.  
This essential in 
maintaining normal 
mitochondrial biogenesis 
and function. 
Self-identified 
African 
Americans 
with ESRD 
were 
recruited 
from 
Wake Forest–
affiliated and 
Emory School 
of Medicine–
affiliated 
outpatient 
hemodialysis 
facilities in 
northwestern 
North 
Carolina 
and Atlanta, 
Georgia 
Presence of both risk 
alleles vs none or 
only one have OR of 
10.5 for FSGS risk 
232–234
 
PDSS2 rs973457 
rs2500574 
P = 0.001 OR 
= 2.6 
P = 0.008 OR 
= 2.2 
Involved with coenzyme 
Q Synthesis which is 
essential for 
mitochondrial function  
Subjects 
were 
recruited 
from 21 US-
based 
academic 
medical 
centers as 
part of the 
National 
Institutes of 
Health (NIH) 
FSGS Genetic 
CoQ10 expression is 
decreased in FSGS 
independently of 
PDSS2 haplotype 
235
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Study 
ESRD 
 
 
 
 
COQ5 rs1167726 
 
rs614226 
P = 1.00×10
−6 
 
P = 1.00×10
−6
 
Essential component of 
ETC 
 
 
All people 
included in 
the analysis 
were of white 
European 
origin and 
were 
diagnosed 
with T1DM 
before the 
age of 31 
years 
Associated with both 
diabetic kidney 
disease and end-stage 
renal disease in the 
discovery and in silico 
replication analyses 
subjects with T1DM 
75
 
COX6A1 rs12310837 
 
P = 2.00×10
−6
 
75
 
GATC rs2235222 
 
rs7137953 
P = 3.00×10
−6 
 
P = 3.00×10
−6
 
75
 
TOP1MT rs724037 
 
P = 2.00×10
−5
 
75
 
PACRG rs2147653 P = 0.003 
75
 
APOL1 G1 allele 
(rs73885319 
and 
rs60910145) 
 
 
G2 allele 
(rs71785313) 
P = 1.1 × 10
−39 
 
 
 
 
 
P = 8.8×10
−18 
 
Encodes a secreted high 
density lipoprotein which 
binds to apolipoprotein 
A-I. Apolipoprotein A-I is 
a relatively abundant 
plasma protein and is the 
major apoprotein of HDL.  
This essential in 
maintaining normal 
mitochondrial biogenesis 
and function. 
Self-identified 
African 
Americans 
with ESRD 
were 
recruited 
from 
Wake Forest–
affiliated and 
Emory School 
of Medicine–
affiliated 
outpatient 
hemodialysis 
facilities in 
northwestern 
North 
Carolina 
and Atlanta, 
Georgia 
2 vs 1 risk alleles  
OR = 5.8  
 
2 vs 0 risk alleles  
OR = 7.3  
 
1vs 0 risk alleles  
OR = 1.26  
232–234
 
SLC22A2 rs316009 P = 0.042  
OR 1.23  
(95% CI: 1.02–
1.48)  
Evidence for 
mitochondrial localisation 
This study 
was 
conducted in 
the REGaTTA 
cohort and all 
cases of renal 
transplantatio
n carried out 
in the 
University 
Medical 
Center 
Groningen in 
1993–2008 
were 
Polyspecific organic 
cation transporters in 
the liver, kidney, 
intestine, and other 
organs are critical for 
elimination of many 
endogenous small 
organic cations as 
well as a wide array 
of drugs and 
environmental toxins.  
Found primarily in the 
kidney, where it may 
mediate the first step 
in cation 
236
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SNP - Single Nucleotide Polymorphism ; eGFR – Estimated Glomerular filtration rate; RS – Reference SNP ID; P – P-value; OR 
– Odds Ratio; CI – Confidence Interval; GWAS – Genome Wide Association Study; GENIE – Genetics of Nephropathy an 
International Effort; UK-ROI – United Kingdom and Republic of Ireland cohort; FinnDiane – Finnish Diabetic Nephropathy 
Study; GoKinD – Genetics of Kidneys in Diabetes ; DNA – Deoxyribonucleic Acid; DM - Diabetes Mellitus; CKD – Chronic 
Kidney Disease; T2DM – Type 2 Diabetes Mellitus; DKD – Diabetic Kidney Disease; ESRD – End Stage Renal Disease; T1DM – 
Type 1 Diabetes Mellitus; SURGENE – Survival Genetic Nephropathy; ROS – Reactive Oxygen Species; HLA – Human 
Leukocyte Antigen; ER – Endoplasmic Reticulum; IgA – Immunoglobulin A; Mtor – mechanistic target of rapamycin; HDL – 
high-density lipoproteins ; FSGS – Focal segmental glomerulosclerosis; ETC – Electron Transport Chain; REGaTTA – Renal 
GeneTics TrAnsplantation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
considered 
for inclusion 
reabsorption. 
RGMA - 
MCTP2 
rs12437854 P = 2.0×10
−9  
OR 1.80  
(95% CI: 1.48–
2.17)   
RGMA localises to 
mitochondria and may 
play a role as a tumor 
suppressor in some 
cancers  
3 discovery 
cohorts from 
GENIE 
consortium: 
UK-ROI, 
FinnDiane and 
GoKinD US 
Associated with time 
from T1DM diagnosis 
to development of 
macroalbuminuria. 
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Table1: Nuclear encoded genes influencing mitochondrial function and reported to be involved with chronic kidney disease 
Biological 
Process 
Gene Physiological Role   Expression in Chronic Kidney Disease (CKD) Pathological Effect  
Mitochondrial 
Biogenesis 
and Function 
PPARGC1A Regulates expression of: TFAM; 
COX6C; COX7C; UQCRH; MCAD; 
NFE2L2; SIRT3; NRF11 
Downregulated in PBMC of CKD undergoing 
PD compared to healthy subjects (p < 
0.001)2; 
Transcriptional coactivator.  Interacts with several 
transcription factors to regulate mitochondrial biogenesis1  
Downregulation may be induced by ROS as a protective 
adaption to reduce further ROS generation2,3 Downregulation 
of PGC1α will also effect expression of downstream genes 
NRF1 Transcription factor which acts with  
PPARGC1A  to stimulate expression 
of a range of nuclear genes involved 
with mitochondrial biogenesis and 
function1,2  Main regulator of 
TFAM2 
Downregulated in PBMC of CKD patients 
undergoing PD compared to healthy subjects 
(p < 0.001)2 
Decreased expression of NRF-1 along with PGC1α will reduce 
expression of downstream targets of these genes and reduced 
mitochondrial biogenesis and OXPHOS activity in 
mitochondria which may be an attempt to reduce ROS 
production and oxidative stress2,4 
TFAM Expression regulated by NRF1; 
Regulates mitochondrial 
transcription and replication   
Downregulated in PBMC of CKD undergoing 
peritoneal dialysis (PD) compared to healthy 
subjects (p < 0.001)2 
Reduced TFAM expression will alter mitochondrial 
transcription and replication machinery and reduce the 
mtDNA copy number5  
NFE2L2 Transcription factor which regulates 
the expression of numerous 
antioxidant/detoxifying enzymes 
including SOD26 
Upregulated in PD compared to controls 2  
Reduced activity increases oxidative stress 
and inflammation whereas increased 
expression may protect against this damage 
in CKD7 
Increased NFE2L2 expression may protect against oxidative 
damage and confer anti-inflammatory properties. Mice 
models have also demonstrated that deletion of this gene 
may lead to lupus-like autoimmune nephritis7,8  Increased 
expression in CKD may be an attempt to neutralise ROS 
production8 
SOD2 Superoxide dismutase (SOD) 
catalyses the dismutation of 
superoxide anions to oxygen and 
hydrogen peroxide – an important 
antioxidant defence mechanism 
Upregulated in PD compared to controls2  
Evidence to suggest gene expression is 
unaffected in CKD but protein content 
decreased from Stage 1 – 4 CKD and then 
increased again in Stage 5 CKD9 
SOD inactivation may compromise mitochondrial function and 
reduce mitochondrial biogenesis and reduce antioxidant 
ability of mitochondria and increase ROS9  Increased 
expression in CKD may be an attempt to neutralise ROS 
production8 
NDUFS5; 
NDUFA6; 
NDUFA1; 
NDUFB1 
NADH:Ubiquinone Oxidoreductase 
Subunit S5; Subunit A6; Subunit A1; 
Subunit B1 – subunits of Complex I  
Up-regulated in CKD patients in conservative 
treatment and HD compared to healthy 
subjects (p < 0.001, FDR = 1%)10 
Increased expression of components of Complex I may be a 
compensatory response to dysregulated OXPHOS in an 
attempt to restore the electrochemical gradient in the outer 
side of the inner mitochondrial membrane10 
UQCRH Ubiquinol-Cytochrome C Reductase 
Hinge Protein – Complex III Subunit 
VIII  
Downregulated in PBMC of CKD undergoing 
PD compared to healthy subjects (p < 
0.001)2  Up-regulated in PBMC of CKD (stage 
4-5) patients in conservative treatment and 
HD compared to CKD stage 2 – 3 and healthy 
subjects (p < 0.001, FDR = 1%)10 
Downregulation may be a protective response against 
increased ROS generation and chronic cellular perturbation 
associated with oxidative injury2  Upregulation in PBMC may 
be an attempt to compensate for reduced OXPHOS activity or 
altered expression due to Haemodialysis treatment)10.  
Statistically significant difference in mRNA levels of UQCRH 
between CKD 2–3 and healthy subjects10 
UQCRB Ubiquinol-Cytochrome C Reductase 
Binding Protein – Complex III 
Subunit VI 
Up-regulated in PBMC of CKD (stage 4 – 5) 
patients in conservative treatment and HD 
compared to CKD stage 2 – 3 and healthy 
subjects (p < 0.001, FDR = 1%)10 
Upregulation in PBMC may be an attempt to compensate for 
reduced OXPHOS activity or altered expression due to 
haemodialysis treatment)10 
COX6C; 
COX7C 
Cytochrome c oxidase subunit 6C; 
subunit 7C – Subunits of complex IV  
Downregulated in PBMC of CKD patients 
undergoing PD compared to healthy subjects 
(p < 0.001) 2  Up-regulated in PBMC of CKD 
(stage 4 – 5) patients in conservative 
treatment and haemodialysis (HD) 
compared to CKD stage 2 – 3 and healthy 
subjects (p < 0.001, FDR = 1%)10 
Complex IV activity was significantly reduced in conservative 
treatment/HD patients and in PD patients compared to 
healthy subjects which may indicate reduced OXPHOS activity 
in CKD2,10  Higher levels of reactive oxygen species and 8-
hydroxydeoxyguanosine in CKD stage 4 – 5 and HD patients 
compared to healthy controls which suggests increased 
oxidative stress in CKD10 
ATP5I, 
ATP5J, 
ATP5O 
ATP Synthase, H+ Transporting, 
Mitochondrial Fo Complex Subunit 
E (ATP5I); Subunit F6 (ATP5J); O 
Subunit (ATP5O) – subunits of 
Complex V 
Up-regulated in CKD patients in conservative 
treatment and HD compared to healthy 
subjects (p < 0.001, FDR = 1%)10 
Increased expression of Complex V components may be a 
compensatory response to defective OXPHOS. This increased 
expression may also lead to increased ROS generation and 
oxidative stress further damaging mitochondria through a 
vicious cycle 
MCAD Medium Chain Acyl CoA 
Dehydrogenase 
Downregulated in PBMC of CKD undergoing 
peritoneal dialysis PD compared to healthy 
subjects (p < 0.001)2 
MCAD catalyzes the first step of mitochondrial fatty acid beta-
oxidation and is an oxidoreductase enzyme regulated by 
PGC1-α.  Downregulation of this will decrease the breakdown 
of fatty acid molecules in mitochondria 
AIFM1 Codes for Apoptosis inducing factor 
(AIF) which is a mitochondrial 
flavoprotein with dual roles in 
redox signalling and programmed 
cell death
11,12
 
Downregulated in CKD13 Partial knockdown disrupts mitochondrial bioenergetics, 
induces mitochondrial fusion and increases mitochondrial ATP 
content and leads to excess production of ROS.  Complete 
inactivation disrupts complex 1 formation resulting in 
OXPHOS defects, however, expression of PGC-1α  and TFAM 
was not changed, suggesting that mitochondrial biogenesis is 
not altered by AIF knockdown13 
APOL1 Reduces SOD2 and Catalase 
expression14 
Increased expression of renal risk variants 
G1 and G2 in various renal complications 
including CKD14 
Decreased SOD2 may exacerbate mitochondrial damage by 
ROS15,16  G1 and G2 risk variants associated with renal disease 
amongst the African Diaspora likely due to the protection 
against African sleeping sickness provided by these 
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PBMC – peripheral blood mononuclear cell; CKD – chronic kidney disease; PD – peritoneal dialysis; HD - haemodialysis; ROS – reactive 
oxygen species; OXPHOS – oxidative phosphorylation; mtDNA – mitochondrial DNA; ECM – extracellular matrix  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
variants14,17–19 
NOX4  Main isoform of NADPH oxidase 
expressed in kidneys 
Key source of ROS and important 
component in Redox signalling20 
Up-regulation in CKD associated with AIFM1 
deletion13,20 
Uncontrolled ROS generation may damage mitochondria 
therefore leading to further ROS production through a vicious 
cycle20,21 
RMND1  Protein encoded by this gene is 
localized in the mitochondria and 
involved in mitochondrial 
translation.  
Genetic variants implicated in multisystem 
failure due to mitochondrial dysfunction – 
including renal complications PD compared 
to controls22–28 
Mutations in this gene are associated with combined 
oxidative phosphorylation deficiency and mitochondrial 
dysfunction of varying severity – Of the reported cases, seven 
had renal involvement additional to mitochondrial 
dysfunction at or earlier than 18 months of age.  3 patients 
with renal dysfunction where found to be homozygous for a 
c.1349G>C, p.450Serext*32 stop-extension mutation in 
RMND122–28 
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Supplementary Table 2: Examples of DNA damage and protective mechanisms   
 
DNA; Deoxyribonucleic acid; ROS – Reactive Oxygen Species; RNS – Reactive Nitrogen Species; HSPs – Heat Shock Proteins; UV – 
Ultraviolet; DSB – Double strand break; SSB – Single strand break. 
 
Type of Genome alteration  Source of damage   Effect on DNA  Repair Mechanism  
Oxidative/ nitrosative stress 
by free radical damage  
ROS/RNS resulting in oxidative/nitrosative stress  Production of 8-oxoguanine resulting in G>T 
substitutions  
Base excision repair, antioxidant 
defences and repair by HSPs  
Hydrolytic Damage  Depurination/Depyrimidation  BP substitutions  Base excision repair 
Deamination  Hydrolytic damage resulting in spontaneous 
removal of the entire amine group from a base.  
Cytosine > Uracil  
Adenine > Hypoxanthine  
Guanine > Thymine  
5-methylcytosine > thymine (concentrated in 
CpG islands and 
involved with DNA 
methylation.  
Base excision repair 
Pyrimidine dimers   UV induced damage resulting in dimerization of  Introduce local conformational changes in 
DNA structure and interfere with base 
pairing during DNA replication. 
Photolyase reactivation or 
nucleotide excision repair 
Alkylation or Bulky Adducts  Resulting from exposure to polycyclic aromatic 
hydrocarbons from atmospheric pollutants such 
as those present in cigarette smoke  
Bind covalently to proteins, lipids, and 
guanine residues of DNA to form DNA 
adducts  
Nucleotide excision repair 
Single-strand breaks, small 
base damage  
Genotoxic agents such as ionizing radiation, 
oxidizing agents, and alkylating agents 
May lead to substitutions and DSB in  Base excision repair  
Interstrand crosslinks  Covalent linkage of two strands by bi-functional 
alkylating agents 
Interfere with cellular metabolism, such as 
DNA replication and transcription, triggering 
cell death. 
Homologous recombination  
Double-stand breaks  Large DNA deletions due to damage by radiation 
such as UV or other genotoxic agents. May also 
occur when replication forks encounter SSBs. 
Chromosome Rearrangements  Homologous recombination (in 
mid-S phase or mid G2 phase of 
mitosis) / Non-homologous end 
joining (In G0, G1 and G2 
phases) 
Mismatches  Base substitution mismatches and insertion-
deletion mismatches which occur during DNA 
replication 
Introduce major changes in the canonical 
recognition rules, and may alter structure 
and stability of the DNA helix 
Mismatch Repair 
Telomere attrition  Part of the aging process but may be expediated 
by smoking, obesity, stress and environmental 
pollutants  
Replicative senescence, accelerated aging 
and reduction in tumour suppressor 
mechanisms.  
Telomerase reverse 
transcriptase / RecQ  
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